GGrantIndex
← Search

Cancer Center Support Grant

$213,244P30FY2014CANIH

Rbhs -Cancer Institute Of New Jersey, New Brunswick NJ

Investigators

Linked publications, trials & patents

Trial NCT05639972Trial NCT05483491Trial NCT05296421Trial NCT04929015Trial NCT04920344Trial NCT04871516Trial NCT04751747Trial NCT04445844Trial NCT04294264Trial NCT04285268Trial NCT04253483Trial NCT04211259Trial NCT04179227Trial NCT04163952Trial NCT04146038Trial NCT04081688Trial NCT03902379Trial NCT03725449Trial NCT03677739Trial NCT03456843Trial NCT03448224Trial NCT03441321Trial NCT03428802Trial NCT03272633Trial NCT03257163Trial NCT03233555Trial NCT03229278Trial NCT03228147Trial NCT03112668Trial NCT03108911Trial NCT03102060Trial NCT03061175Trial NCT03028948Trial NCT02949284Trial NCT02885649Trial NCT02748564Trial NCT02699996Trial NCT02688517Trial NCT02688192Trial NCT02621398Trial NCT02526511Trial NCT02526498Trial NCT02458716Trial NCT02421575Trial NCT02420652Trial NCT02324621Trial NCT02324608Trial NCT02315196Trial NCT02295540Trial NCT02294617Trial NCT02250781Trial NCT02203604Trial NCT02203578Trial NCT02177838Trial NCT02144701Trial NCT02144675Trial NCT02105116Trial NCT01828476Trial NCT01694589Trial NCT01652014Trial NCT01649947Trial NCT01480154Trial NCT01417286Trial NCT01407562Trial NCT01303341Trial NCT01251172Trial NCT01032590Trial NCT01018836Trial NCT01009931Trial NCT01006369Trial NCT00996359Trial NCT00991315Trial NCT00966667Trial NCT00962845Trial NCT00946283Trial NCT00943709Trial NCT00939380Trial NCT00934895Trial NCT00909909Trial NCT00905918Trial NCT00900120Trial NCT00899808Trial NCT00899639Trial NCT00895115Trial NCT00891969Trial NCT00878657Trial NCT00866840Trial NCT00853125Trial NCT00813423Trial NCT00786682Trial NCT00770419Trial NCT00770055Trial NCT00769652Trial NCT00765765Trial NCT00749437Trial NCT00740805Trial NCT00728845Trial NCT00726596Trial NCT00669734Trial NCT00667901

Abstract

DESCRIPTION (provided by applicant): The tobacco industry is relying on product and marketing innovation to drive future growth. The electronic or e- cigarette market provides a much needed area of growth for tobacco manufacturers, including the major cigarette manufacturers. The cigar market is another potential area for growth given the extensive variety of products available. E-cigarettes and cigars are not currently subject to the same FDA regulations as cigarettes and as result, the flavorings, product descriptors; and packaging in these markets vary more widely. In addition, the marketing strategies for e-cigarettes appear to highlight their potential for harm reduction. Such marketing will likely stimulate demand as well as questions to providers from patients about the safety of-cigarettes. Marketing of e-cigarettes has also become more mainstream as more brands are nationally advertised. Brand as well as flavor and packaging are also particularly important to cigar users. This revision application describes a plan to conduct three individual research projects that provide scientific data that can inform FDA regulation of e-cigarettes and cigars. These three projects respond to four of the FDA Center for Tobacco Products' research interest areas identified in the FOA including areas 2 (cigar use and perceptions), 4 (e-cigarette use and perceptions), 6 (impact of tobacco product characteristics on initiation) and 10 (effective communication strategies regarding the risk of tobacco products). Specifically, we plan to examine patient-provider communication related to e-cigarettes, explore the influence of ecigarette marketing on consumer perceptions and product trial, and investigate the impact of cigar product characteristics on young adults' cigar use and perceptions. Quantitative and qualitative data will be collected on the multiple factors that potentially influence the use of these products. Thus, the significance of this proposed research is its potential to generate a better understanding of e-cigarette and cigar use and perceptions which is vital to informing FDA tobacco product regulation.

View original record on NIH RePORTER →